Mitsui Fudosan Co Ltd (MFU.HA)
| Previous close | 8.40 |
| Open | 8.45 |
| Bid | 8.50 x N/A |
| Ask | 8.80 x N/A |
| Day's range | 8.45 - 8.45 |
| 52-week range | 5.83 - 10.10 |
| Volume | |
| Avg. volume | 8 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 02 Aug 2024 - 06 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireAstellas, BioLabs and Mitsui Fudosan Announce a Collaboration to Enhance the Life Science Ecosystems in Tsukuba and Kashiwa-no-ha, Japan
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and BioLabs Global, Inc. (Founder and CEO: Johannes Fruehauf, "BioLabs") and Mitsui Fudosan (TSE: 8801, President and CEO: Takashi Ueda, "Mitsui Fudosan") today announced that they have agreed on a tri-party memorandum of understanding to enhance the life science ecosystem in Tsukuba and Kashiwa-no-ha, Japan, world-renowned science hubs. With this agreement, the three companies will partner to advance SakuLabTM-Tsukub
- PR Newswire
Astellas Establishes Open Innovation Hub for Tumor Microenvironment Research with Cutting-Edge Spatial Biology, in Mitsui Fudosan's "MITSUI LINK-Lab KASHIWA-NO-HA 1"
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Mitsui Fudosan Co., Ltd. (TSE: 8801, President and CEO: Takashi Ueda, "Mitsui Fudosan") announced today that Astellas will establish a "TME imaging and interactive research for innovation (TME iLab)" open innovation hub in October, 2023 in "MITSUI LINK-Lab KASHIWA-NO-HA 1" (Kashiwa City, Chiba Prefecture, "the Lab") operated by Mitsui Fudosan.
